enGene’s (ENGN) Market Outperform Rating Reiterated at JMP Securities

enGene (NASDAQ:ENGN)‘s stock had its “market outperform” rating reissued by equities researchers at JMP Securities in a note issued to investors on Monday,Benzinga reports. They currently have a $18.00 price objective on the stock. JMP Securities’ target price points to a potential upside of 208.75% from the company’s previous close.

ENGN has been the topic of several other reports. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Raymond James assumed coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. HC Wainwright started coverage on enGene in a research note on Monday. They set a “buy” rating and a $25.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $29.78.

enGene Stock Down 2.2 %

Shares of ENGN stock opened at $5.83 on Monday. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The stock has a market cap of $257.78 million, a price-to-earnings ratio of -10.05 and a beta of -0.78. The firm’s 50-day moving average is $8.13 and its 200-day moving average is $7.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Sell-side analysts predict that enGene will post -1.52 EPS for the current year.

Insider Buying and Selling at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were bought at an average price of $6.55 per share, for a total transaction of $77,578.20. Following the purchase, the insider now owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This trade represents a 0.48 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the completion of the transaction, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 420,965 shares of company stock valued at $2,651,103 in the last ninety days. 13.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its stake in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares in the last quarter. Wolverine Asset Management LLC bought a new stake in enGene during the 3rd quarter worth $37,000. Logos Global Management LP raised its position in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Finally, SR One Capital Management LP acquired a new stake in shares of enGene during the second quarter valued at about $4,715,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.